+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Anti-Parkinson's Disease Drugs Market - Global Forecast 2026-2032- Product Image
Anti-Parkinson's Disease Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Anti-Parkinson's Disease Drugs Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6146804
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Anti-Parkinson's Disease Drugs Market is projected to reach USD 6.91 Billion in 2026. It is expected to continue growing at a CAGR of 10.61%, reaching USD 12.84 Billion by 2032.

Anti-Parkinson’s Disease Drugs: Executive Overview

Anti-Parkinson’s disease drugs address the motor and non-motor symptoms associated with Parkinson’s disease, a progressive neurological disorder. Treatment commonly involves dopaminergic medicines, adjunctive therapies, and symptom-specific interventions. Clinical decision-making depends on disease stage, age, cognitive status, comorbidities, treatment response, and tolerability. The therapeutic landscape is evolving toward more individualized regimens, improved delivery systems, and better management of fluctuations and dyskinesia.

Treatment Is Shifting Toward Individualized, Longitudinal Care

The landscape is moving beyond a single-drug approach toward coordinated management across disease stages. Clinicians increasingly balance symptom control with risks such as hallucinations, impulse-control disorders, orthostatic hypotension, dyskinesia, and cognitive decline. Extended-release formulations, infusion-based options, device-assisted delivery, rehabilitation, and multidisciplinary care are becoming more important components of treatment planning. Earlier recognition of non-motor symptoms and improved continuity between neurology, primary care, pharmacy, and rehabilitation services are also reshaping care pathways.

Artificial Intelligence Strengthens Monitoring and Treatment Personalization

Artificial intelligence can support anti-Parkinson’s disease care by identifying patterns in clinical notes, imaging, speech, gait, tremor, sleep, and wearable-sensor data. These applications may help characterize symptom fluctuations, support earlier referral, and inform treatment adjustments between clinic visits. However, clinical usefulness depends on representative datasets, transparent validation, privacy safeguards, interoperability, and clinician oversight. AI should complement-not replace-neurological assessment, shared decision-making, and monitoring for adverse effects.

Regional Differences Reflect Access, Diagnosis, and Care Infrastructure

North America generally benefits from specialized neurology services, digital monitoring capabilities, and broader access to advanced therapies, although affordability and care fragmentation remain concerns. Europe combines strong clinical research and multidisciplinary services with variation in reimbursement, referral pathways, and national treatment guidance. Asia-Pacific includes sophisticated specialist systems alongside substantial unmet needs in rural and lower-resource settings, with Japan, Australia, South Korea, China, and India reflecting different demographic and healthcare conditions. Latin America faces uneven specialist coverage, medicine access, and diagnostic capacity. The Middle East shows expanding investment in tertiary and digital healthcare, while access varies considerably across countries. Africa continues to face major challenges involving specialist shortages, diagnostic delays, medicine availability, and continuity of care.

International Groupings Reveal Uneven Policy and Access Priorities

Within ASEAN, differences in healthcare financing, specialist availability, and urban-rural access shape treatment continuity. BRICS countries span diverse disease burdens, pharmaceutical systems, and public-sector capabilities, making local manufacturing, affordability, and workforce development important considerations. The European Union benefits from regulatory coordination and cross-border research, while national reimbursement and service delivery remain distinct. G7 members generally have advanced clinical infrastructure but continue to address aging populations, affordability, and capacity constraints. GCC countries are strengthening specialized care and digital health infrastructure, with access patterns differing by national systems and expatriate populations. NATO members represent varied healthcare models, but shared priorities include continuity of care, aging-related neurological needs, and resilient medicine supply chains.

Country Contexts Shape Diagnosis, Access, and Treatment Continuity

Australia and Canada must address geographic dispersion and specialist access, while Brazil and Mexico face regional inequalities and pressure on public treatment pathways. China is expanding neurological services and digital health capabilities, with access varying across urban and rural areas. France, Germany, Italy, Spain, and the United Kingdom combine established neurology networks with differing reimbursement, referral, and waiting-time arrangements. India faces a substantial need for earlier diagnosis, trained specialists, affordable medicines, and rural outreach. Japan and South Korea have strong medical infrastructure but must manage aging-related demand and long-term care coordination. Russia’s care environment is shaped by regional differences and supply-chain considerations. The United States offers extensive specialist and advanced-treatment capacity, alongside significant affordability, insurance, and care-coordination challenges.

Prioritize Accessible, Measurable, Patient-Centered Treatment Pathways

Industry leaders should develop therapies and delivery systems that address both motor fluctuations and non-motor symptoms while simplifying long-term use. Evidence generation should include diverse populations, real-world outcomes, quality-of-life measures, caregiver burden, and treatment persistence. Partnerships with healthcare providers can strengthen diagnostic education, adherence support, rehabilitation access, and remote monitoring. Digital and AI-enabled tools should be introduced with clinical validation, cybersecurity, explainability, and clear escalation pathways. Organizations should also plan for resilient supply chains, transparent value communication, equitable access programs, and region-specific implementation models rather than relying on a uniform global approach.

Methodology Combines Clinical Evidence With Health-System Context

This executive summary uses the defined anti-Parkinson’s disease drugs market scope and synthesizes verified, publicly available evidence from clinical literature, regulatory materials, treatment guidelines, health-system publications, and reputable epidemiological sources. Analysis considers therapeutic classes, care pathways, technology adoption, access conditions, demographic trends, and regional healthcare infrastructure. Qualitative comparisons are framed around documented differences in diagnosis, reimbursement, specialist capacity, and treatment delivery. No market estimates, market sizing, market shares, forecasts, or company-specific claims are included.

The Next Phase Requires Better Integration Across Therapy, Data, and Care

Anti-Parkinson’s disease treatment is progressing toward more personalized and continuous management, but outcomes remain closely linked to diagnosis, affordability, specialist access, and coordinated support. Advances in formulations, delivery technologies, monitoring, and AI may improve care when integrated with rigorous clinical oversight. Leaders should focus on clinically meaningful outcomes, equitable implementation, and durable partnerships across patients, caregivers, clinicians, health systems, and policymakers. The strongest progress will come from combining therapeutic innovation with practical improvements in everyday care.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Anti-Parkinson's Disease Drugs Market, by Drug Class
7.1. Introduction
7.2. Amantadine
7.3. Anticholinergics
7.3.1. Benztropine
7.3.2. Trihexyphenidyl
7.4. Catechol-O-Methyltransferase Inhibitors
7.4.1. Entacapone
7.4.2. Opicapone
7.4.3. Tolcapone
7.5. Dopamine Agonists
7.5.1. Ergot-Derived
7.5.2. Non-Ergot-Derived
7.6. Monoamine Oxidase B Inhibitors
7.6.1. Rasagiline
7.6.2. Safinamide
7.6.3. Selegiline
8. Anti-Parkinson's Disease Drugs Market, by Administration Route
8.1. Introduction
8.2. Injectable
8.3. Oral
8.3.1. Extended Release
8.3.2. Immediate Release
8.4. Transdermal
9. Anti-Parkinson's Disease Drugs Market, by Therapy Type
9.1. Introduction
9.2. Combination Therapy
9.3. Monotherapy
10. Anti-Parkinson's Disease Drugs Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacies
10.3. Online Pharmacies
10.4. Retail Pharmacies
11. Anti-Parkinson's Disease Drugs Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Anti-Parkinson's Disease Drugs Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Anti-Parkinson's Disease Drugs Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AbbVie Inc.
15.2. Alembic Pharma Ltd.
15.3. Amneal Pharmaceuticals LLC
15.4. Apotex Inc.
15.5. AstraZeneca PLC
15.6. Aurobindo Pharma Ltd.
15.7. Bayer AG
15.8. Bristol-Myers Squibb Company
15.9. Dr. Reddy’s Laboratories Ltd.
15.10. Eli Lilly and Company
15.11. Emcure Pharmaceuticals Ltd.
15.12. GlaxoSmithKline plc
15.13. Hikma Pharmaceuticals plc
15.14. Intas Pharmaceuticals Ltd.
15.15. Lundbeck A/S
15.16. Lupin Limited
15.17. Merck & Co., Inc.
15.18. Mylan N.V.
15.19. Novartis AG
15.20. Pfizer Inc.
15.21. Roche Holding AG
15.22. Sandoz International GmbH
15.23. Sanofi
15.24. Shilpa Medicare Ltd.
15.25. Sun Pharmaceutical Industries Ltd.
15.26. Takeda Pharmaceutical Company Limited
15.27. Teva Pharmaceutical Industries Ltd.
15.28. Viatris Inc.
15.29. Zydus Lifesciences Ltd.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Anti-Parkinson's Disease Drugs Market, Years Considered for the Study
FIGURE 2. Global Anti-Parkinson's Disease Drugs Market, Research Design
FIGURE 3. Global Anti-Parkinson's Disease Drugs Market, Research Framework
FIGURE 4. Global Anti-Parkinson's Disease Drugs Market, Data Triangulation
FIGURE 5. Global Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2025 vs 2032 (%)
FIGURE 7. Global Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2025 vs 2032 (%)
FIGURE 9. Global Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2025 vs 2032 (%)
FIGURE 11. Global Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Anti-Parkinson's Disease Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Anti-Parkinson's Disease Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Anti-Parkinson's Disease Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Anti-Parkinson's Disease Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Anti-Parkinson's Disease Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Anti-Parkinson's Disease Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Anti-Parkinson's Disease Drugs Market Segmentation & Coverage
TABLE 2. Global Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 4. Global Amantadine Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Amantadine Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Amantadine Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Anticholinergics Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Anticholinergics Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Anticholinergics Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Benztropine Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Benztropine Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Benztropine Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Trihexyphenidyl Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Trihexyphenidyl Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Trihexyphenidyl Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Catechol-O-Methyltransferase Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Catechol-O-Methyltransferase Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Catechol-O-Methyltransferase Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Entacapone Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Entacapone Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Entacapone Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Opicapone Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Opicapone Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Opicapone Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Tolcapone Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Tolcapone Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Tolcapone Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Dopamine Agonists Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Dopamine Agonists Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Dopamine Agonists Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Ergot-Derived Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Ergot-Derived Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Ergot-Derived Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Non-Ergot-Derived Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Non-Ergot-Derived Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Non-Ergot-Derived Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Monoamine Oxidase B Inhibitors Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Monoamine Oxidase B Inhibitors Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Monoamine Oxidase B Inhibitors Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Rasagiline Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Rasagiline Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Rasagiline Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Safinamide Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Safinamide Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Safinamide Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Selegiline Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Selegiline Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Selegiline Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 50. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Oral Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Oral Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Oral Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Extended Release Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Extended Release Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Extended Release Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Immediate Release Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Immediate Release Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Immediate Release Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Transdermal Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Transdermal Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Transdermal Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 66. Global Combination Therapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Combination Therapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Combination Therapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Monotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 70. Global Monotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 71. Global Monotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 72. Global Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 73. Global Hospital Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Hospital Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Hospital Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Online Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Online Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Online Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Retail Pharmacies Market Size, by Region, 2017-2032 (USD Million)
TABLE 80. Global Retail Pharmacies Market Size, by Group, 2017-2032 (USD Million)
TABLE 81. Global Retail Pharmacies Market Size, by Country, 2017-2032 (USD Million)
TABLE 82. Global Anti-Parkinson's Disease Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 88. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 89. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 90. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 91. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 92. Asia-Pacific Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 93. North America Anti-Parkinson's Disease Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. North America Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 95. North America Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 96. North America Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 97. North America Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 98. North America Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 99. North America Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 100. North America Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 101. North America Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 102. North America Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 103. Latin America Anti-Parkinson's Disease Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Latin America Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 105. Latin America Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 106. Latin America Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 107. Latin America Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 108. Latin America Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 109. Latin America Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 110. Latin America Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 111. Latin America Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 112. Latin America Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 113. Europe Anti-Parkinson's Disease Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 114. Europe Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 115. Europe Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 116. Europe Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 117. Europe Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 118. Europe Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 119. Europe Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 120. Europe Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 121. Europe Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 122. Europe Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 123. Middle East Anti-Parkinson's Disease Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 124. Middle East Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 125. Middle East Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 126. Middle East Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 127. Middle East Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 128. Middle East Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 129. Middle East Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 130. Middle East Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 131. Middle East Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 132. Middle East Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 133. Africa Anti-Parkinson's Disease Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 134. Africa Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 135. Africa Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 136. Africa Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 137. Africa Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 138. Africa Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 139. Africa Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 140. Africa Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 141. Africa Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 142. Africa Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 143. Global Anti-Parkinson's Disease Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. ASEAN Anti-Parkinson's Disease Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. ASEAN Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 146. ASEAN Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 147. ASEAN Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 148. ASEAN Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 149. ASEAN Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 150. ASEAN Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 151. ASEAN Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 152. ASEAN Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 153. ASEAN Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 154. GCC Anti-Parkinson's Disease Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 155. GCC Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 156. GCC Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 157. GCC Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 158. GCC Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 159. GCC Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 160. GCC Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 161. GCC Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 162. GCC Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 163. GCC Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. European Union Anti-Parkinson's Disease Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 165. European Union Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 166. European Union Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 167. European Union Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 168. European Union Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 169. European Union Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 170. European Union Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 171. European Union Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 172. European Union Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 173. European Union Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 174. BRICS Anti-Parkinson's Disease Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 175. BRICS Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 176. BRICS Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 177. BRICS Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 178. BRICS Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 179. BRICS Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 180. BRICS Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 181. BRICS Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 182. BRICS Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 183. BRICS Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 184. G7 Anti-Parkinson's Disease Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 185. G7 Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 186. G7 Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 187. G7 Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 188. G7 Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 189. G7 Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 190. G7 Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 191. G7 Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 192. G7 Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 193. G7 Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 194. NATO Anti-Parkinson's Disease Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 195. NATO Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 196. NATO Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 197. NATO Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 198. NATO Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 199. NATO Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 200. NATO Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 201. NATO Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 202. NATO Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 203. NATO Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 204. Global Anti-Parkinson's Disease Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 205. United States Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 206. United States Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 207. United States Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 208. United States Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 209. United States Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 210. United States Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 211. United States Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 212. United States Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 213. United States Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 214. United States Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 215. Canada Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 216. Canada Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 217. Canada Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 218. Canada Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 219. Canada Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 220. Canada Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 221. Canada Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 222. Canada Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 223. Canada Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 224. Canada Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 225. Mexico Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 226. Mexico Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 227. Mexico Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 228. Mexico Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 229. Mexico Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 230. Mexico Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 231. Mexico Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 232. Mexico Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 233. Mexico Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 234. Mexico Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 235. Brazil Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 236. Brazil Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 237. Brazil Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 238. Brazil Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 239. Brazil Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 240. Brazil Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 241. Brazil Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 242. Brazil Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 243. Brazil Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 244. Brazil Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 245. United Kingdom Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 246. United Kingdom Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 247. United Kingdom Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 248. United Kingdom Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 249. United Kingdom Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 250. United Kingdom Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 251. United Kingdom Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 252. United Kingdom Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 253. United Kingdom Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 254. United Kingdom Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 255. Germany Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 256. Germany Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 257. Germany Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 258. Germany Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 259. Germany Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 260. Germany Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 261. Germany Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 262. Germany Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 263. Germany Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 264. Germany Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 265. France Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 266. France Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 267. France Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 268. France Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 269. France Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 270. France Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 271. France Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 272. France Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 273. France Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 274. France Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 275. Russia Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 276. Russia Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 277. Russia Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 278. Russia Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 279. Russia Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 280. Russia Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 281. Russia Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 282. Russia Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 283. Russia Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 284. Russia Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 285. Italy Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 286. Italy Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 287. Italy Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 288. Italy Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 289. Italy Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 290. Italy Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 291. Italy Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 292. Italy Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 293. Italy Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 294. Italy Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 295. Spain Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 296. Spain Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 297. Spain Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 298. Spain Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 299. Spain Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 300. Spain Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 301. Spain Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 302. Spain Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 303. Spain Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 304. Spain Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 305. China Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 306. China Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 307. China Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 308. China Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 309. China Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 310. China Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 311. China Anti-Parkinson's Disease Drugs Market Size, by Administration Route, 2017-2032 (USD Million)
TABLE 312. China Anti-Parkinson's Disease Drugs Market Size, by Oral, 2017-2032 (USD Million)
TABLE 313. China Anti-Parkinson's Disease Drugs Market Size, by Therapy Type, 2017-2032 (USD Million)
TABLE 314. China Anti-Parkinson's Disease Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 315. India Anti-Parkinson's Disease Drugs Market Size, 2017-2032 (USD Million)
TABLE 316. India Anti-Parkinson's Disease Drugs Market Size, by Drug Class, 2017-2032 (USD Million)
TABLE 317. India Anti-Parkinson's Disease Drugs Market Size, by Anticholinergics, 2017-2032 (USD Million)
TABLE 318. India Anti-Parkinson's Disease Drugs Market Size, by Catechol-O-Methyltransferase Inhibitors, 2017-2032 (USD Million)
TABLE 319. India Anti-Parkinson's Disease Drugs Market Size, by Dopamine Agonists, 2017-2032 (USD Million)
TABLE 320. India Anti-Parkinson's Disease Drugs Market Size, by Monoamine Oxidase B Inhibitors, 2017-2032 (USD Million)
TABLE 321. India Anti-Parkinson's Disease Drugs Market Size, b

Companies Mentioned

  • AbbVie Inc.
  • Alembic Pharma Ltd.
  • Amneal Pharmaceuticals LLC
  • Apotex Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • Emcure Pharmaceuticals Ltd.
  • GlaxoSmithKline plc
  • Hikma Pharmaceuticals plc
  • Intas Pharmaceuticals Ltd.
  • Lundbeck A/S
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Roche Holding AG
  • Sandoz International GmbH
  • Sanofi
  • Shilpa Medicare Ltd.
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • Zydus Lifesciences Ltd.

Related Topics

Related Reports

Anti-Parkinson Drugs Market Report 2026 - Product Image

Anti-Parkinson Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Anti-Parkinson Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis - Product Image

Anti-Parkinson Drugs Market Outlook 2025-2034: Market Share, and Growth Analysis

  • Report
  • 160 Pages
  • Global
From
Parkinson's Disease Drugs - Global Strategic Business Report - Product Image

Parkinson's Disease Drugs - Global Strategic Business Report

  • Report
  • 382 Pages
  • Global
From
Parkinson's Disease Drugs Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035) - Product Image

Parkinson's Disease Drugs Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends (2026-2035)

  • Report
  • 350 Pages
  • Global
From
Parkinson's Disease Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Parkinson's Disease Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 115 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.